Zhengsen Jin
Zhongdi Cai
Asma Perveen
George E. Barreto4
Linlin Yin
Rong Wang
Rui Liu- 1Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- 2Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, India
- 3Glocal School of Life Sciences, Glocal University, Saharanpur, Uttar Pradesh, India
- 4Department of Biological Sciences, University of Limerick, Limerick, Ireland
- 5Department of Neuroinfection and Neuroimmunology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- 6Central Laboratory, Xuanwu Hospital, Capital Medical University, Beijing, China
Editorial on the Research Topic
Remedying the injured brain in cognitive impairment: potential neuroimmune communication signaling and therapeutic opportunities
Nearly 16% of the global population suffers from neurological disorders linked to acute or chronic inflammation, including neurodegenerative and cerebral neuroimmune diseases (1, 2). Neuroimmune dysregulation is widely acknowledged as a pivotal mechanism in the pathogenesis of these disorders, involving intricate immune responses and cellular interactions within the central nervous system (CNS) (3). Recent advances at the intersection of neuroscience and immunology have greatly enhanced our understanding of neuroimmune signaling pathways (4). Studies have shown that resident immune cells in the brain, such as microglia and astrocytes, together with peripheral immune cells, including T cells, B cells, and monocytes, play critical roles in neuroinflammation, vascular injury, and cognitive decline (5–7). For instance, the functional states of microglia, such as the pro-inflammatory M1-type and neuroprotective M2-type polarization, as well as their transformation into disease-associated microglia, coupled with aberrant activation of the complement system, are significantly implicated in the progression of neurodegenerative diseases (8). Furthermore, the infiltration of peripheral immune cells and their communication with the CNS remain major themes in neuroimmune research (9, 10). This Research Topic brings together cutting-edge advances in neuroimmune signaling, novel microglial polarization states, peripheral immune system-to-CNS immune crosstalk, and multi-omics biomarkers associated with cognitive impairment and dementia, with a special focus on innovative therapeutic strategies targeting neuroimmune inflammation. The Research Topic includes six papers: four original research papers, one systematic review, and one opinion piece.
Advanced insights into neuroimmune communication signaling in neurological disorders
Advances in sequencing technologies, particularly epitranscriptomic and single-cell sequencing (scRNA-seq), have profoundly improved our understanding of brain cell types, states, and regulatory mechanisms (11, 12). Epigenetic dysfunction leading to altered gene expression in the brain is recognized as a key pathophysiological feature of aging-related neurodegeneration (13). N6-methyladenosine (m6A) RNA methylation and demethylation, the most prevalent internal RNA modifications in eukaryotes, regulate multiple aspects of RNA metabolism and associated signaling pathways (14). Given the strong genetic component of Alzheimer’s disease (AD) and related dementias, Liao et al. demonstrated that chronic intermittent ethanol exposure reduced Th2 immune cells in the brains of AD mice. Using Methylated RNA Immunoprecipitation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq), they further revealed that increased expression of RNA binding motif protein 15B (Rbm15b) and decreased expression of heterogeneous nuclear ribonucleoprotein A2/B1 (Hnrnpa2b1) contributed to synaptic dysfunction and neuroinflammation underlying memory impairment. This study provides an epigenetic link between chronic alcohol consumption and cognitive deficits in AD mice. Beyond inflammation triggered by chronic external factors, intrinsic immune signaling pathways also play crucial roles in AD. Li et al. identified dysregulated expression of multiple NOD-like receptor (NLR) family members in hippocampal RNA-seq data from AD patients. They further confirmed significant upregulation of NLR family pyrin domain-containing 3 (NLRP3) in microglia surrounding amyloid-β plaques in both AD mice and human postmortem tissue. Functional studies of NLRP3 could reveal novel therapeutic avenues for AD. Apart from microglia-centered mechanisms in AD, high-throughput technologies are also being used to identify regulatory targets in other neuroimmune disorders. Yu et al. utilized scRNA-seq to examine transcriptional states and cellular composition of peripheral blood mononuclear cells in multiple sclerosis (MS) patients. Integrated with multiple Mendelian randomization approaches, they identified Fc receptor-like 3 (FCRL3), a B cell-specific receptor, as a potential protective immune node, offering a fresh perspective on immunoregulatory mechanisms in MS.
Therapeutic opportunities targeting neuroimmune pathways in neurological disorders
This Research Topic also highlights therapeutic strategies aimed at immune-inflammatory mechanisms in neurological diseases. Among the myriad of inflammatory mediators, microRNAs (miRNAs), a subset of small non-coding RNAs, are recognized as key regulators of numerous biological processes, owing to their ability to modulate multiple genes simultaneously (15). miRNAs are highly abundant in the CNS, with each cell type exhibiting a distinct expression profile (16). Elucidating the spatiotemporal regulation of miRNAs and their targets under pathological conditions is essential for developing miRNA-based biomarkers and therapeutic interventions. In this Research Topic, Zhao et al. emphasize the role of a novel miRNA, miR-25802, in AD-related neuroinflammation. They demonstrated that miR-25802 upregulation coincides with early microglial activation in AD, suggesting its diagnostic potential. Mechanistically, miR-25802 directly binds to and suppresses Krüppel-like transcription factor 4 (KLF4) mRNA, promoting microglial polarization toward a pro-inflammatory M1 phenotype via nuclear factor κB (NF-κB)-mediated inflammation. The authors also proposed that using AAV9-based delivery of regulators targeting the miR-25802/KLF4/NF-κB axis could offer new treatment strategies for AD. Given the central role of NF-κB in inflammation, Bai et al. conducted a comprehensive bibliometric analysis of 1,468 publications (2008–2023) to delineate the research landscape of NF-κB in cognitive impairment. Their findings identified current and emerging research themes, including neuroinflammation, microglial activation, and NF-κB-mediated signaling networks. The study also noted growing interest in apolipoprotein E, gut microbiota, and ketogenic diet-based interventions, reflecting a shift toward multidisciplinary treatment approaches. As the resident immune cells of the CNS, microglia also participate in neurogenesis, modulation of synaptic plasticity, neuronal network maintenance, and contribute to synapse formation and pruning through the elimination of inactive, weak, or excessive synapses (17). This clearance process depends on microglia triggering receptor expressed on myeloid cells 2 (TREM2), C1q and C3 proteins, and the phagocytic capacity of microglia (18). Zhang et al. revealed that dysregulated phagocytosis in prelimbic microglia affected spine density and glutamatergic signaling, thereby influencing the formation of fear memory. In a fear conditioning model, TREM2 knockout restored synaptic homeostasis, enhanced neuronal function, and improved memory performance, suggesting that targeting TREM2 to modulate microglial activity may represent a promising therapeutic strategy.
Overall, this Research Topic elucidates the critical roles and underlying mechanisms of neuroimmune dysregulation in various CNS disorders, including AD, cognitive impairment, MS, and fear-related psychiatric disorders. With accumulating evidence implicating immune-inflammatory processes in disease progression, we aimed to spotlight advances in neuroimmune signaling, multi-omics biomarkers, and novel therapeutic strategies. The findings underscore the potential of targeting neuroimmune crosstalk, such as through TREM2 modulation, NLRP3 inhibition, or miRNA-based therapies, to alleviate neuroinflammation and cognitive decline. We hope this Research Topic inspires further research into immune-focused diagnostics and treatments, ultimately contributing to effective interventions for neuroinflammatory and neurodegenerative diseases. Finally, we extend our sincere gratitude to the authors, reviewers, and the Editorial Office of Frontiers in Immunology for their outstanding contributions and dedicated support of this Research Topic.
Author contributions
ZJ: Writing – original draft, Writing – review & editing. ZC: Writing – original draft, Writing – review & editing. AP: Writing – review & editing. GB: Writing – review & editing. LY: Writing – review & editing. RW: Writing – review & editing. RL: Conceptualization, Writing – original draft, Writing – review & editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Shi FD and Yong VW. Neuroinflammation across neurological diseases. Science. (2025) 388:eadx0043. doi: 10.1126/science.adx0043
2. Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, and Dewachter I. Hallmarks of neurodegenerative diseases. Cell. (2023) 186:693–714. doi: 10.1016/j.cell.2022.12.032
3. Wheeler MA and Quintana FJ. The neuroimmune connectome in health and disease. Nature. (2025) 638:333–42. doi: 10.1038/s41586-024-08474-x
4. Akassoglou K, Davalos D, Mendiola AS, Petersen MA, Ryu JK, Schachtrup C, et al. Pioneering discovery and therapeutics at the brain-vascular-immune interface. Cell. (2024) 187:5871–6. doi: 10.1016/j.cell.2024.09.018
5. Sepehrinezhad A and Gorji A. Pericyte-glial cell interactions: Insights into brain health and disease. Neural Regener Res. (2026) 21:1253–63. doi: 10.4103/NRR.NRR-D-24-01472
6. Li P, Huang C, He Y, Lei X, Shen X, Xu J, et al. M2 macrophage-laden vascular grafts orchestrate the optimization of the inflammatory microenvironment for abdominal aorta regeneration. Acta Biomater. (2025) S1742-7061:00598–7. doi: 10.1016/j.actbio.2025.08.016
7. Wang Y, Zhang M, Zhang T, Zhang S, Ji F, Qin J, et al. PD-L1/PD-1 checkpoint pathway regulates astrocyte morphogenesis and myelination during brain development. Mol Psychiatry. (2025) 30:3895–911. doi: 10.1038/s41380-025-02969-3
8. Mrdjen D, Cannon BJ, Amouzgar M, Kim Y, Liu C, Vijayaragavan K, et al. Spatial proteomics of Alzheimer’s disease-specific human microglial states. Nat Immunol. (2025) 26:1397–410. doi: 10.1038/s41590-025-02203-w
9. Van Hove H, De Feo D, Greter M, and Becher B. Central nervous system macrophages in health and disease. Annu Rev Immunol. (2025) 43:589–613. doi: 10.1146/annurev-immunol-082423-041334
10. Kaur R, Kumar S, and Singh L. A comprehensive review: neuroinflammation and immune communication between the central nervous system and the periphery. Cytokine. (2025) 192:156974. doi: 10.1016/j.cyto.2025.156974
11. Moquin-Beaudry G, Andriamboavonjy L, Audet S, Hamilton LK, Duquette A, Chouinard S, et al. Mapping the peripheral immune landscape of Parkinson’s disease patients with single-cell sequencing. Brain. (2025) 148:2847–60. doi: 10.1093/brain/awaf066
12. Jiang J, Zhang M, Xia W, Ding C, Li J, Hu X, et al. Fto-mediated m6A modification is essential for cerebellar development through regulating epigenetic reprogramming. J BioMed Sci. (2025) 32:81. doi: 10.1186/s12929-025-01176-0
13. Hwang JY, Aromolaran KA, and Zukin RS. The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat Rev Neurosci. (2017) 18:347–61. doi: 10.1038/nrn.2017.46
14. An Y and Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. (2022) 21:14. doi: 10.1186/s12943-022-01500-4
15. Zhao K, Liu J, Sun T, Zeng L, Cai Z, Li Z, et al. The miR-25802/KLF4/NF-κB signaling axis regulates microglia-mediated neuroinflammation in Alzheimer’s disease. Brain Behav Immun. (2024) 118:31–48. doi: 10.1016/j.bbi.2024.02.016
16. Zeng L, Cai Z, Liu J, Zhao K, Liang F, Sun T, et al. miR-32533 reduces cognitive impairment and amyloid-β Overload by targeting CREB5-mediated signaling pathways in alzheimer’s disease. Adv Sci (Weinh). (2025) 12:e2409986. doi: 10.1002/advs.202409986
17. Marques SI, Sá SI, Carmo H, Carvalho F, and Silva JP. Pharmaceutical-mediated neuroimmune modulation in psychiatric/psychological adverse events. Prog Neuropsychopharmacol Biol Psychiatry. (2024) 135:111114. doi: 10.1016/j.pnpbp.2024.111114
Keywords: Alzheimer’s disease, central nervous system disorders, microglia, multiple sclerosis, neuroimmune signaling, neuroinflammation, therapeutic strategies
Citation: Jin Z, Cai Z, Perveen A, Barreto GE, Yin L, Wang R and Liu R (2025) Editorial: Remedying the injured brain in cognitive impairment: potential neuroimmune communication signaling and therapeutic opportunities. Front. Immunol. 16:1705628. doi: 10.3389/fimmu.2025.1705628
Received: 15 September 2025; Accepted: 22 September 2025;
Published: 30 September 2025.
Edited and reviewed by:
Robert Weissert, University of Regensburg, GermanyCopyright © 2025 Jin, Cai, Perveen, Barreto, Yin, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Linlin Yin, eWlubGlubGluQGJqdHRoLm9yZw==; Rong Wang, cm9uZ193YW5nNzJAYWxpeXVuLmNvbQ==; Rui Liu, bGl1cnVpQGltYi5wdW1jLmVkdS5jbg==
†These authors have contributed equally to this work and share first authorship